TLSA Tiziana Life Sciences plc

6.09
+0.28  (+5%)
Previous Close 5.81
Open 6.09
Price To Book -19.64
Market Cap 83106460
Shares 13,646,381
Volume 106
Short Ratio
Av. Daily Volume 1,104

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 trial initiation announced November 28, 2018.
Foralumab
NASH (healthy human volunteers)
Phase 2a completion of enrolment announced December 3, 2018. Top-line data due 2Q 2019.
Milciclib
Hepatocellular carcinoma (HCC)
Phase 2b trial to be initiated 1Q 2019.
Milciclib and Sorafenib (Nexavar)
Hepatocellular carcinoma (HCC)